{'52WeekChange': -0.39295644,
 'SandP52WeekChange': None,
 'address1': '5500 Flatiron Parkway',
 'address2': 'Suite 100',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.22,
 'askSize': 1400,
 'averageDailyVolume10Day': 3788387,
 'averageVolume': 6419331,
 'averageVolume10days': 3788387,
 'beta': 2.47675,
 'beta3Year': None,
 'bid': 6.2,
 'bidSize': 3100,
 'bookValue': -1.728,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boulder',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.5699,
 'dayLow': 6.13,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.402,
 'enterpriseToRevenue': 5.609,
 'enterpriseValue': 855027776,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '303 245 0360',
 'fiftyDayAverage': 6.788857,
 'fiftyTwoWeekHigh': 17.37,
 'fiftyTwoWeekLow': 2.93,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 69723771,
 'forwardEps': -2.46,
 'forwardPE': -2.5,
 'fromCurrency': None,
 'fullTimeEmployees': 484,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0227,
 'heldPercentInstitutions': 0.48459,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/clovisoncology.com',
 'longBusinessSummary': 'Clovis Oncology, Inc., a biopharmaceutical company, '
                        'focuses on acquiring, developing, and commercializing '
                        'anti-cancer agents in the United States, the European '
                        'Union, and internationally. The company offers '
                        'Rubraca (rucaparib), an oral small molecule inhibitor '
                        'of poly ADP-ribose polymerase for recurrent '
                        'epithelial ovarian, fallopian tube, or primary '
                        'peritoneal cancer. It also provides lucitanib, an '
                        'oral inhibitor of the tyrosine kinase activity of '
                        'vascular endothelial growth factor receptors, '
                        'platelet-derived growth factor receptors alpha and '
                        'beta, and fibroblast growth factor receptors. The '
                        'company distributes its products primarily through '
                        'specialty distributors and pharmacy providers to '
                        'patients and health care providers. Clovis Oncology, '
                        'Inc. has license agreements with Pfizer Inc., '
                        'AstraZeneca UK Limited, and Advenchen Laboratories '
                        'LLC; collaboration agreements with Bristol-Myers '
                        'Squibb Company and Myriad Genetics, Inc.; and a '
                        'partnership with Foundation Medicine, Inc. The '
                        'company was founded in 2009 and is headquartered in '
                        'Boulder, Colorado.',
 'longName': 'Clovis Oncology, Inc.',
 'market': 'us_market',
 'marketCap': 541144000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_59220391',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -413335008,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.5,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.02,
 'phone': '303 625 5000',
 'previousClose': 6.55,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 3.5496025,
 'profitMargins': -2.71125,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.5699,
 'regularMarketDayLow': 6.13,
 'regularMarketOpen': 6.5,
 'regularMarketPreviousClose': 6.55,
 'regularMarketPrice': 6.5,
 'regularMarketVolume': 4388336,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 87990896,
 'sharesPercentSharesOut': 0.3437,
 'sharesShort': 30244846,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 27239015,
 'shortName': 'Clovis Oncology, Inc.',
 'shortPercentOfFloat': 0.3538,
 'shortRatio': 6.22,
 'startDate': None,
 'state': 'CO',
 'strikePrice': None,
 'symbol': 'CLVS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -7.058,
 'twoHundredDayAverage': 7.590791,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a7e23eb6-a092-374f-8e85-81019076b4da',
 'volume': 4388336,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.clovisoncology.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '80301'}